Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Cysic Cysic +22.50%
#4 Bedrock Bedrock +19.73%
#5 Velvet Velvet +19.00%
#6 Fabric Protocol Fabric Protocol +16.39%
#7 Nockchain Nockchain +16.19%
#8 Perle Perle +13.72%
#9 Versatize Coin Versatize Coin +12.49%
#10 Starpower Starpower +12.07%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Medesis Pharma S.A. Medesis Pharma S.A.

Medesis Pharma S.A.

ALMDP
Rank in Stocks #37493
Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development... Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to creating orally delivered molecular drug therapies aimed at critical medical conditions lacking effective treatments. The company's pipeline features several innovative compounds, including NanoLithium (NP03), which is currently undergoing clinical trials for Alzheimer's disease, and NanosiRNA DH, targeting Huntington's Disease. Medesis Pharma also develops NU01 Plutonium and NU02 Cesium for nuclear decorporation, alongside NP02 – NanoManganese, a radioprotection medication designed for individuals exposed to radiation from nuclear incidents. Furthermore, their portfolio encompasses NanosiRNA COVID-19, an antiviral solution for various viral infections, and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for oncological applications. Established in 2003, the enterprise operates from its headquarters in Montpellier, France.
Share Price
$0.38207938
Last synced: 2025-04-07
Market Cap
$1.67M
Change (1 day)
-0.39%
Change (1 year)
0.00%
Country
FR
Trade Medesis Pharma S.A. (ALMDP)

Category

Healthcare
Earnings for Medesis Pharma S.A. (ALMDP)
Earnings in 2026 TTM: 0
According to Medesis Pharma S.A. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Medesis Pharma S.A. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE